Did BionTech cheat? Harsh accusations against Biontch/Pfizer – Whistleblower criticizes sloppiness in approval study
A whistleblower has now made serious accusations against Biontech and Pfizer. The allegations seem to involve incorrectly stored vaccines, problems with laboratory samples and slow follow-up of side effects. All of these accusations apparently come from a former employee of a US company who accuses Biontech and Pfizer of sloppiness in the approval study of the Corona vaccine. Despite this, both experts and regulatory agencies see the vaccine as proven effective.
Whistleblower Accuses Biontech/Pfizer of Sloppiness in Approval of Imofacient
In the journal “The BMJ” had been published the information of a whistleblower who had been employed in the fall of 2020 about two weeks at the US company Ventavia. This company had conducted a small part of the study on behalf of the US pharmaceutical company Pfizer, which ultimately led to the approval of the vaccine. Now the former employee Brook Jackson accuses the company Ventavia of having generated false vaccination data. The former employee comes to this conclusion because laboratory samples were mislabeled, the vaccine was stored incorrectly, and Ventavia was slow to investigate reports of possible side effects. Biontech told the German newspaper “Bild” that it was currently investigating the case internally and could neither confirm nor deny the woman’s statements. The US company Ventavia confirmed that Brook Jackson had worked for the company in September 2020. There, too, they want to investigate the allegations of the woman now. Ventavia has a total of 3 locations in the US state of Texas. Ventavia was one of a total of 166 institutions that had cared for participants during Pfizer’s vaccine trial. Ventavia was supposed to be responsible for 1,000 of the total of about 44,000 test persons. This represents just 2.3 percent of all subjects.
Experts consider vaccine effectiveness proven
.
The U.S. Food and Drug Administration (FDA) also declined to comment on the journal article, saying only that it had confidence in the pharmaceutical company’s data that led to the approval of Biontech/Pfizer’s Corona vaccine. The European Medicines Agency (EMA) said it was putting the
the safety, efficacy and quality of the vaccine was not in question because of the publication. Peter Kremsner, from the Institute of Tropical Medicine also comments on the case. The medical expert also sees no reason to doubt the quality of the approval study. “What the whistleblower has uncovered is without question unpalatable,” emphasizes Kremsner, who, however, does not want to question the data because of this. “It’s just not enough for me. The vaccination data has already been confirmed in numerous studies,” Kremsner explains his point of view. Kremsner blamed the time pressure in the search for a vaccine for the sloppiness. Oliver Cornely, the scientific director of the Center for Clinical Studies Cologne, has a similar point of view. “The errors described in “The BMJ” article do not limit the validity of the vaccine’s approval study,” the expert clarifies. Because in practice the vaccine has proven itself. “We hardly ever admit vaccinated persons as inpatients because of Covid-19, so we recognize the effectiveness every day,” Cornely makes a clear judgment. Nevertheless, he suggested better regulatory controls for the subcontractors involved in the approval process.